Literature DB >> 1634244

Arthritis induced in rats with adjuvant oil is a genetically restricted, alpha beta T-cell dependent autoimmune disease.

R Holmdahl1, T J Goldschmidt, S Kleinau, C Kvick, R Jonsson.   

Abstract

Adjuvant arthritis in rats is usually induced by injection of mycobacterium tubercle cell walls suspended in various adjuvant oils such as Freund's incomplete adjuvant (FIA) or pristane. We have recently shown that injection of adjuvant oils without inclusion of mycobacterium tubercle cell walls triggers arthritis [oil adjuvant-induced arthritis (OIA)] in the DA rat strain. The OIA is a genetically restricted disease since only DA rats are susceptible while Lewis, DA-fostered Lewis and F1 (Lew x DA) rats are relatively resistant. Activated alpha beta T cells infiltrate the affected joints of adjuvant oil-injected DA rats and treatment with monoclonal antibodies to the alpha beta T-cell receptor abrogates development of arthritis. These findings show that alpha beta T-cell activation is a critical event in the development of OIA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1634244      PMCID: PMC1421552     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  39 in total

Review 1.  A cartilage-mimicking T-cell epitope on a 65K mycobacterial heat-shock protein: adjuvant arthritis as a model for human rheumatoid arthritis.

Authors:  W van Eden; E J Hogervorst; E J Hensen; R van der Zee; J D van Embden; I R Cohen
Journal:  Curr Top Microbiol Immunol       Date:  1989       Impact factor: 4.291

2.  Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies.

Authors:  R Holmdahl; K Rubin; L Klareskog; E Larsson; H Wigzell
Journal:  Arthritis Rheum       Date:  1986-03

3.  The purification and characterization of rat gamma interferon by use of two monoclonal antibodies.

Authors:  P H van der Meide; M Dubbeld; K Vijverberg; T Kos; H Schellekens
Journal:  J Gen Virol       Date:  1986-06       Impact factor: 3.891

4.  Suppressive effect of Escherichia coli on adjuvant-induced arthritis in germ-free rats.

Authors:  O Kohashi; Y Kohashi; T Takahashi; A Ozawa; N Shigematsu
Journal:  Arthritis Rheum       Date:  1986-04

5.  Adjuvant-induced arthritis in rats. Evidence that autoimmunity to homologous collagens types I, II, IX and XI is not involved in the pathogenesis of arthritis.

Authors:  M A Cremer; A S Townes; A H Kang
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

6.  Rat cytomegalovirus infection enhances type II collagen arthritis in rats.

Authors:  C B Smith; M M Griffiths; L S Wei
Journal:  Arthritis Rheum       Date:  1986-10

7.  Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.

Authors:  J W Kupiec-Weglinski; T Diamantstein; N L Tilney; T B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

8.  Appearance of different lymphoid cells in synovial tissue and in peripheral blood during the course of collagen II-induced arthritis in rats.

Authors:  R Holmdahl; K Rubin; L Klareskog; L Dencker; G Gustafson; E Larsson
Journal:  Scand J Immunol       Date:  1985-03       Impact factor: 3.487

9.  Early appearance of activated CD4+ T lymphocytes and class II antigen-expressing cells in joints of DBA/1 mice immunized with type II collagen.

Authors:  R Holmdahl; R Jonsson; P Larsson; L Klareskog
Journal:  Lab Invest       Date:  1988-01       Impact factor: 5.662

10.  Autoimmunity to type II collagen an experimental model of arthritis.

Authors:  D E Trentham; A S Townes; A H Kang
Journal:  J Exp Med       Date:  1977-09-01       Impact factor: 14.307

View more
  23 in total

1.  Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes.

Authors:  C Vingsbo; P Sahlstrand; J G Brun; R Jonsson; T Saxne; R Holmdahl
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 2.  Rodent models of arthritis: relevance for human disease.

Authors:  R O Williams
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

Review 3.  Role of superantigens in experimental arthritis.

Authors:  A Abdelnour; Y X Zhao; T Bremell; R Holmdahl; A Tarkowski
Journal:  Springer Semin Immunopathol       Date:  1996

4.  Identification of rat susceptibility loci for adjuvant-oil-induced arthritis.

Authors:  J C Lorentzen; A Glaser; L Jacobsson; J Galli; H Fakhrai-rad; L Klareskog; H Luthman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

5.  CD8+ cells suppress oil-induced arthritis.

Authors:  A M Jansson; J C Lorentzen; A Bucht
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

6.  A new animal model for relapsing polychondritis, induced by cartilage matrix protein (matrilin-1).

Authors:  A S Hansson; D Heinegård; R Holmdahl
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

7.  Percutaneous exposure of adjuvant oil causes arthritis in DA rats.

Authors:  S Kleinau; H Erlandsson; L Klareskog
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

8.  Adjuvant oil induces waves of arthritogenic lymph node cells prior to arthritis onset.

Authors:  B C Holm; J C Lorentzen; A Bucht
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

9.  Cartilage oligomeric matrix protein (COMP)-induced arthritis in rats.

Authors:  S Carlsén; A S Hansson; H Olsson; D Heinegård; R Holmdahl
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

10.  gammadelta T cells contribute to the systemic immunoglobulin E response and local B-cell reactivity in allergic eosinophilic airway inflammation.

Authors:  Linda Svensson; Bo Lilliehöök; Roland Larsson; Anders Bucht
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.